Treatment Decision-Making Based on the COMMANDS Trials

Author(s):

Guillermo Garcia-Manero, MD,Rami Komrokji, MD

The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP: 4.Review of the COMMANDS Trial

EP: 5.Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

Now Viewing

EP: 7.Treatment Decision-Making Based on the COMMANDS Trials

EP: 8.Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

EP: 9.Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP: 10.Safety Profile of Available Frontline Treatments LR-MDS

EP: 11.1L treatment of lower-risk MDS beyond luspatercept

EP: 12.Sequencing Second-Line Treatments for LR-MDS

EP: 13.Perspectives of IMerge Study

EP: 14.Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP: 15.EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP: 16.Final Thoughts on EHA 2024 Data for Lower-Risk MDS

How does the COMMANDS trial and outcomes on erythroid, neutrophil, and platelet lineages impact your treatment decision-making?
How does the genomic landscape and mutational burden impact clinical outcomes of luspatercept from the COMMANDS trial?